xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05983302</url>
    </required_header>
    <id_info>
      <org_study_id>IR.MUMS.REC.1402.089</org_study_id>
      <nct_id>NCT05983302</nct_id>
    </id_info>
    <brief_title>Elimination of Odor and Treatment of Malodorous Recalcitrant Wounds by Using Supraz and PRP-FG Versus Standard of Care</brief_title>
    <official_title>Repairing Gel (Supraz) and Platelet-rich Plasma-Fibrin Glue (PRP-FG) in Eliminating Odor and Healing the Malodorous Chronic Wounds Versus Standard of Care</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Mashhad University of Medical Sciences</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Aristotle University Of Thessaloniki</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Mashhad University of Medical Sciences</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The aim of this study is to eliminate the malodorous of chronic wound and increase the chance&#xD;
        of the healing of recalcitrant wounds by using the repairing gel (supraz gel) which has the&#xD;
        approved components in wound healing and platelet-rich plasma-fibrin glue.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The current study assesses the effects of platelet-rich plasma-fibrin glue (PRP-FG) along&#xD;
        with the use of the repairing gel which has the approved components on wound healing in&#xD;
        patients with chronic wounds and to eliminate the malodorous of chronic wound. This&#xD;
        randomized controlled trial is performed on patients with chronic wounds. Patients will be&#xD;
        treated with repairing gel (supraz gel) plus PRP-FG dressing (intervention group) or only&#xD;
        Supraz gel (intervention group) or only PRP-FG dressing (intervention group) every 48 hours&#xD;
        for 8 weeks versus standard of care of treatment (control group: irrigation of wound by&#xD;
        normal saline 0.9%).&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Anticipated">August 20, 2023</start_date>
    <completion_date type="Anticipated">March 20, 2024</completion_date>
    <primary_completion_date type="Anticipated">January 20, 2024</primary_completion_date>
    <phase>Phase 2/Phase 3</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Factorial Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Wound Odor Change</measure>
      <time_frame>At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)</time_frame>
      <description>Change from Baseline Wound Odor intensity at 2 months will be assessed by the nurse using a Visual Analog Scale (VAS) from 0 to 100 (perceived odor).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Wound Size Change</measure>
      <time_frame>At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)</time_frame>
      <description>Change from Baseline Wound Size (length and width) at 2 months will be assessed in digital images taken of the wound.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Visual Analog Scale changes for pain assessment</measure>
      <time_frame>Every 48 hours for 8 weeks</time_frame>
      <description>Pain will be evaluated by the visual analog scale system (VAS) which assesses changes in pain via a continuous measurement instrument. The score is determined by measuring the distance (mm) between the no-pain anchor to the point that the patient marks, providing a range of scores from 0 - 10. A higher score indicates greater pain intensity.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Duration of recovery</measure>
      <time_frame>8 weeks</time_frame>
      <description>The duration of recovery, which is the number of days it will be taken for the wound to heal.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change in the systemic inflammatory marker C-reactive protein (CRP)</measure>
      <time_frame>At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)</time_frame>
      <description>C-reactive protein (CRP)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change in systemic inflammatory marker erythrocyte sedimentation rate (ESR)</measure>
      <time_frame>At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)</time_frame>
      <description>erythrocyte sedimentation rate (ESR)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change in systemic inflammatory marker Interleukin 6 (IL-6)</measure>
      <time_frame>At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)</time_frame>
      <description>Interleukin 6 (IL-6)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Number of participants with infection</measure>
      <time_frame>At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)</time_frame>
      <description>A swab culture: Identify a small area (1 cm) of clean viable tissue and rotate the swab on it for 5 seconds while applying enough pressure to produce exudate and culture it to detect bacteria.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Results of the SF36 questionnaire at inclusion</measure>
      <time_frame>Day 0</time_frame>
      <description>The SF-36 questionnaire is a quality-of-life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Results of the SF36 questionnaire at Month 2</measure>
      <time_frame>Month 2</time_frame>
      <description>The SF-36 questionnaire is a quality-of-life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Percentage rate of re-epithelialization</measure>
      <time_frame>Participants will be followed for the duration of 8 weeks</time_frame>
      <description>Pictures taken of the wound site every other day will be analyzed using imaging software for the size of the wound. The percentage rate will be calculated from this.</description>
    </secondary_outcome>
    <number_of_arms>4</number_of_arms>
    <enrollment type="Anticipated">40</enrollment>
    <condition>Wounds and Injuries</condition>
    <arm_group>
      <arm_group_label>Platelet-Rich Plasma-Fibrin Glue</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>The first intervention group (group A) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing platelet-rich plasma-fibrin glue intervention for 8 weeks.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Repairing Gel</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>The second intervention group (group B) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing repairing gel intervention for 8 weeks. The components of repairing gel are vitamin A - vitamin C - vitamin B3 - glycine amino acid. - ethanol - collagen - citric acid - glycerin - malic acid - urea - carboxymethyl cellulose - Sodium alginate - Benzoic acid - Allantoin - Bromelain - Methylene blue - Violet dimethyl sulfoxide . The formulation is patented. (PCT, IR108458)</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Platelet-Rich Plasma-Fibrin Glue and Repairing Gel</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>The third intervention group (group C) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing the repairing gel with approved wound healing components and platelet-fibrin glue for 8 weeks.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Classical wound irrigation (control)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>For 10 patients with chronic wounds, only classical wound irrigation by normal saline (0.9%) will be continued for 8 weeks.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Platelet-Rich Plasma-Fibrin Glue</intervention_name>
      <description>The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.</description>
      <arm_group_label>Platelet-Rich Plasma-Fibrin Glue</arm_group_label>
      <other_name>PRP-FG</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Repairing Gel</intervention_name>
      <description>The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.</description>
      <arm_group_label>Repairing Gel</arm_group_label>
      <other_name>Supraz Gel</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Repairing Gel and Platelet-Rich Plasma-Fibrin Glue</intervention_name>
      <description>The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.</description>
      <arm_group_label>Platelet-Rich Plasma-Fibrin Glue and Repairing Gel</arm_group_label>
      <other_name>Supraz Gel and PRP-FG</other_name>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Classical wound irrigation (control)</intervention_name>
      <description>For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.</description>
      <arm_group_label>Classical wound irrigation (control)</arm_group_label>
      <other_name>Control</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Having a single wound on the body that has been at least 3 months old and has not been&#xD;
               repaired by wound irrigation with normal saline and changing the dressing&#xD;
  &#xD;
            -  Having a body mass index of 18-35&#xD;
  &#xD;
            -  Sign the informed consent by the patient&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Having concurrent diseases that may cause problems in wound healing, such as cancers,&#xD;
               vasculitis, kidney and liver failure, and heart failure&#xD;
  &#xD;
            -  Taking certain drugs that may interfere with wound healing, such as corticosteroids,&#xD;
               immunosuppressive agents, and cytotoxic agents&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>N/A</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Daryoush Hamidi Alamdari, Ph.D</last_name>
      <role>Principal Investigator</role>
      <affiliation>Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
    </overall_official>
    <overall_official>
      <last_name>George Koliakos, MD, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Daryoush Hamidi Alamdari, Ph.D</last_name>
      <phone>+98 9151017650</phone>
      <email>hamidiad@mums.ac.ir</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Elaheh Emadi, Ph.D</last_name>
      <phone>+98 9355850931</phone>
      <email>EmadiE4001@mums.ac.ir</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Medical School, Aristotle University of Thessaloniki</name>
        <address>
          <city>Thessaloniki</city>
          <country>Greece</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>George Koliakos, MD, PhD</last_name>
        <phone>00306944677745</phone>
        <email>koliakos@yahoo.gr</email>
      </contact>
    </location>
    <location>
      <facility>
        <name>Mashhad University of Medical Sciences</name>
        <address>
          <city>Mashhad</city>
          <state>Razavi Khorasan</state>
          <zip>99191-91778</zip>
          <country>Iran, Islamic Republic of</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Daryoush Hamidi Alamdari, Ph.D</last_name>
        <phone>00989151017650</phone>
        <email>hamidiad@mums.ac.ir</email>
      </contact>
      <contact_backup>
        <last_name>Elaheh Emadi, Ph.D</last_name>
        <phone>98 9355850931</phone>
        <email>EmadiE4001@mums.ac.ir</email>
      </contact_backup>
      <investigator>
        <last_name>George Koliakos, MD, Ph.D</last_name>
        <role>Sub-Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>Greece</country>
      <country>Iran, Islamic Republic of</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>June 30, 2023</study_first_submitted>
    <study_first_submitted_qc>August 1, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 9, 2023</study_first_posted>
    <last_update_submitted>August 1, 2023</last_update_submitted>
    <last_update_submitted_qc>August 1, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 9, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
      <investigator_full_name>Daryoush Hamidi Alamdari, PhD</investigator_full_name>
      <investigator_title>Associate professor</investigator_title>
    </responsible_party>
    <keyword>Platelet-Rich Plasma-Fibrin Glue</keyword>
    <keyword>Repairing Gel</keyword>
    <keyword>Chronic Wounds</keyword>
    <keyword>Malodorous</keyword>
    <keyword>Recalcitrant</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Wounds and Injuries</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Fibrin Tissue Adhesive</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>All data related to the project after the unidentifiable people will be shared.</ipd_description>
      <ipd_info_type>Study Protocol</ipd_info_type>
      <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
      <ipd_time_frame>Access to data is allowed 6 months after the publication of results.</ipd_time_frame>
      <ipd_access_criteria>The investigator's data will be available to university staff and academic institutions.</ipd_access_criteria>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05983302
  org study id: IR.MUMS.REC.1402.089
  nct id: NCT05983302
  lead sponsor: 
  collaborator: 
  is fda regulated drug: No
  is fda regulated device: No
  The aim of this study is to eliminate the malodorous of chronic wound and increase the chance
        of the healing of recalcitrant wounds by using the repairing gel (supraz gel) which has the
        approved components in wound healing and platelet-rich plasma-fibrin glue.
  The current study assesses the effects of platelet-rich plasma-fibrin glue (PRP-FG) along
        with the use of the repairing gel which has the approved components on wound healing in
        patients with chronic wounds and to eliminate the malodorous of chronic wound. This
        randomized controlled trial is performed on patients with chronic wounds. Patients will be
        treated with repairing gel (supraz gel) plus PRP-FG dressing (intervention group) or only
        Supraz gel (intervention group) or only PRP-FG dressing (intervention group) every 48 hours
        for 8 weeks versus standard of care of treatment (control group: irrigation of wound by
        normal saline 0.9%).
  allocation: Randomized
  intervention model: Factorial Assignment
  primary purpose: Treatment
  masking: Triple (Participant, Investigator, Outcomes Assessor)
  measure: Wound Odor Change
  time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)
  description: Change from Baseline Wound Odor intensity at 2 months will be assessed by the nurse using a Visual Analog Scale (VAS) from 0 to 100 (perceived odor).
  measure: Wound Size Change
  time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)
  description: Change from Baseline Wound Size (length and width) at 2 months will be assessed in digital images taken of the wound.
  measure: Visual Analog Scale changes for pain assessment
  time frame: Every 48 hours for 8 weeks
  description: Pain will be evaluated by the visual analog scale system (VAS) which assesses changes in pain via a continuous measurement instrument. The score is determined by measuring the distance (mm) between the no-pain anchor to the point that the patient marks, providing a range of scores from 0 - 10. A higher score indicates greater pain intensity.
  measure: Duration of recovery
  time frame: 8 weeks
  description: The duration of recovery, which is the number of days it will be taken for the wound to heal.
  measure: Change in the systemic inflammatory marker C-reactive protein (CRP)
  time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)
  description: C-reactive protein (CRP)
  measure: Change in systemic inflammatory marker erythrocyte sedimentation rate (ESR)
  time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)
  description: erythrocyte sedimentation rate (ESR)
  measure: Change in systemic inflammatory marker Interleukin 6 (IL-6)
  time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)
  description: Interleukin 6 (IL-6)
  measure: Number of participants with infection
  time frame: At the beginning of the study (0 day) and at the end of the eighth week of the intervention (8 weeks)
  description: A swab culture: Identify a small area (1 cm) of clean viable tissue and rotate the swab on it for 5 seconds while applying enough pressure to produce exudate and culture it to detect bacteria.
  measure: Results of the SF36 questionnaire at inclusion
  time frame: Day 0
  description: The SF-36 questionnaire is a quality-of-life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.
  measure: Results of the SF36 questionnaire at Month 2
  time frame: Month 2
  description: The SF-36 questionnaire is a quality-of-life questionnaire that includes 36 questions divided into 8 different categories (physical functioning, limitations due to physical condition, physical pain, perceived health, vitality, social functioning or well-being, limitations due to mental condition, mental health). These 8 dimensions are used to calculate two scores on the quality of life of individuals: the physical composite score and the mental composite score. The higher the score, the greater the capacity. It is self-administered and takes less than 10 minutes. Higher scores indicate better quality of life. The French version has been validated and has satisfactory psychometric properties. Score from 0 to 100.
  measure: Percentage rate of re-epithelialization
  time frame: Participants will be followed for the duration of 8 weeks
  description: Pictures taken of the wound site every other day will be analyzed using imaging software for the size of the wound. The percentage rate will be calculated from this.
  arm group label: Platelet-Rich Plasma-Fibrin Glue
  arm group type: Experimental
  description: The first intervention group (group A) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing platelet-rich plasma-fibrin glue intervention for 8 weeks.
  arm group label: Repairing Gel
  arm group type: Experimental
  description: The second intervention group (group B) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing repairing gel intervention for 8 weeks. The components of repairing gel are vitamin A - vitamin C - vitamin B3 - glycine amino acid. - ethanol - collagen - citric acid - glycerin - malic acid - urea - carboxymethyl cellulose - Sodium alginate - Benzoic acid - Allantoin - Bromelain - Methylene blue - Violet dimethyl sulfoxide . The formulation is patented. (PCT, IR108458)
  arm group label: Platelet-Rich Plasma-Fibrin Glue and Repairing Gel
  arm group type: Experimental
  description: The third intervention group (group C) includes 10 patients with chronic wounds who, despite classic wound irrigation treatment, will be undergoing the repairing gel with approved wound healing components and platelet-fibrin glue for 8 weeks.
  arm group label: Classical wound irrigation (control)
  arm group type: Experimental
  description: For 10 patients with chronic wounds, only classical wound irrigation by normal saline (0.9%) will be continued for 8 weeks.
  intervention type: Drug
  intervention name: Platelet-Rich Plasma-Fibrin Glue
  description: The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
  arm group label: Platelet-Rich Plasma-Fibrin Glue
  other name: PRP-FG
  intervention type: Drug
  intervention name: Repairing Gel
  description: The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
  arm group label: Repairing Gel
  other name: Supraz Gel
  intervention type: Drug
  intervention name: Repairing Gel and Platelet-Rich Plasma-Fibrin Glue
  description: The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
  arm group label: Platelet-Rich Plasma-Fibrin Glue and Repairing Gel
  other name: Supraz Gel and PRP-FG
  intervention type: Other
  intervention name: Classical wound irrigation (control)
  description: For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
  arm group label: Classical wound irrigation (control)
  other name: Control
  criteria: 
  gender: All
  minimum age: N/A
  maximum age: N/A
  healthy volunteers: No
  last name: Daryoush Hamidi Alamdari, Ph.D
  role: Principal Investigator
  affiliation: Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  last name: George Koliakos, MD, PhD
  role: Principal Investigator
  affiliation: Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  last name: Daryoush Hamidi Alamdari, Ph.D
  phone: +98 9151017650
  email: hamidiad@mums.ac.ir
  last name: Elaheh Emadi, Ph.D
  phone: +98 9355850931
  email: EmadiE4001@mums.ac.ir
  facility: 
  status: Not yet recruiting
  contact: 
  facility: 
  status: Recruiting
  contact: 
  contact backup: 
  investigator: 
  country: Greece
  country: Iran, Islamic Republic of
  responsible party type: Principal Investigator
  investigator affiliation: Mashhad University of Medical Sciences
  investigator full name: Daryoush Hamidi Alamdari, PhD
  investigator title: Associate professor
  mesh term: Wounds and Injuries
  mesh term: Fibrin Tissue Adhesive
  sharing ipd: Yes
  ipd description: All data related to the project after the unidentifiable people will be shared.
  ipd info type: Study Protocol
  ipd info type: Informed Consent Form (ICF)
  ipd time frame: Access to data is allowed 6 months after the publication of results.
  ipd access criteria: The investigator's data will be available to university staff and academic institutions.